BioSpace News Archive

Jasmine Harvey, 21, was born with the complex congenital heart condition tetralogy of Fallot and underwent open-heart surgery at St. Joseph’s Children’s Hospital when she was just 4-months-old.

STERIBITE, LLC announced it has gained controlling interest via a merger with Precision Manufacturing Group, LLC, a contract manufacturer in Wooster, Ohio.

Progenity, Inc., a biotechnology company innovating in the field of oral biotherapeutics for gastrointestinal health and beyond, announced it has successfully closed the business divestiture of its affiliate Avero Diagnostics through an asset sale to Northwest Pathology.

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the company has initiated a global Phase 2 study to evaluate the safety and efficacy of lumasiran, an RNAi therapeutic targeting hydroxyacid oxidase 1 (HAO1) – the gene encoding glycolate oxidase (GO) – in patients with recurrent kidney stone disease and elevated urinary oxalate levels.

DBV Technologies S.A., a clinical-stage biopharmaceutical company, announced plans to initiate a new, pivotal Phase 3 clinical study for a modified Viaskin™ Peanut patch in children in the intended patient population.

Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio” or the “Company”), a biopharmaceutical company pioneering Tissue Specific Therapeutics (TSTx)TM targeting oncology and immuno-dysregulated diseases, today announced the closing of its initial public offering of 4,200,000 shares of its common stock at a public offering price of $5.00 per share.

A recently published research article in Nature Aging by a Cleveland Clinic Genomic Medicine Institute (GMI) research team, led by Feixiong Cheng, Ph.D., entitled “Endophenotype-based in silico network medicine discovery combined with insurance record data mining identifies sildenafil as a candidate drug for Alzheimer’s disease” showed the potential of PDE5 Inhibitors in Alzheimer’s Disease (AD).

Deficiency of Vitamin D is a common issue faced by many across the globe. It is more common amongst the older adults.

The demand within the global market for single-use airway diagnostic devices has been rising on account of advancements in the manufacturing dynamics of medical devices.

Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today announced that the U.S. Food and Drug Administration (FDA) has granted clearance to proceed with a Phase 1b clinical trial using STI-1386, Seprehvec™, entitled “Dose Escalation Study of the Safety and Preliminary Efficacy of STI-1386 Oncolytic Virus in Patients with Relapsed or Refractory Solid Tumors.”